
    
      This study was prematurely discontinued for futility on 23 January 2009, based on a planned
      interim analysis by an independent Data Safety Monitoring Board (DSMB) that found no evidence
      of improvement in the primary endpoint (survival) in patients treated with axitinib and
      gemcitabine compared to gemcitabine alone. Enrollment on this study has been discontinued.
    
  